First, cancer genome sequencing has demonstrated disruption of this pathway through CDKN2A deletion, a potential biomarker of sensitivity to CDK4/6 inhibitors [40], in approximately 13–30 percent of Ewing sarcoma tumors [10, 11, 41, 42]. This evidence concerns the gene CDK4 and cancer.